In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Harvard University

https://www.harvard.edu/

Latest From Harvard University

Arena BioWorks Wants To Address Inefficiency Of Early R&D Finance

Backed with $500m to look into the mechanistic underpinnings of unmet medical needs, Arena BioWorks will employ a hub-and-spoke model to incubate biotechs around a central technology hub.

Business Strategies Financing

Sickle Cell Drug Development Gains Momentum Across Disease Spectrum

The recent ASH meeting began with US FDA approvals of the first genetic medicines for sickle cell disease, but doctors and biopharma companies still see a need for new oral therapies and other options. 

Clinical Trials Rare Diseases

Finance Watch: October Begins With A VC Mega-Round For Newly Named Iambic

Private Company Edition: Iambic, formerly known as Entos, closed a $100m series B venture capital round to advance its AI-discovered therapeutics. Also, Evozyne raised $81m and Acesion brought in €45m in series B rounds, while Mogrify added $10m to bring its series A to $46m.

Financing Artificial Intelligence

Deal Watch: Moderna, Immactics Team Up To Combine mRNA Technology With Cancer Cell Therapy

Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Academic and Research Institutions
UsernamePublicRestriction

Register